Victory Square portfolio company Insu Therapeutics wins USPTO patent allowance for buccal peptide delivery platform
Bitget2026/10/08 11:31Victory Square portfolio company Insu Therapeutics received a USPTO Notice of Allowance for its buccal peptide-delivery patent application. Allowance supports InsuTab buccal insulin and BuccaGLP buccal semaglutide programs aimed at replacing injections with mouth-lining absorption. Insu holds an exclusive worldwide UBC license; Hydreight has disclosed exclusive U.S. distribution rights, subject to development and approvals. Hydreight made a strategic investment of C$ 300,000 in Insu, disclosed in March 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Victory Square Technologies Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: VA66593) on October 08, 2026, and is solely responsible for the information contained therein.
- Victory Square portfolio company Insu Therapeutics received a USPTO Notice of Allowance for its buccal peptide-delivery patent application.
- Allowance supports InsuTab buccal insulin and BuccaGLP buccal semaglutide programs aimed at replacing injections with mouth-lining absorption.
- Insu holds an exclusive worldwide UBC license; Hydreight has disclosed exclusive U.S. distribution rights, subject to development and approvals.
- Hydreight made a strategic investment of C$ 300,000 in Insu, disclosed in March 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
